|
Session 127
Poster Abstracts
ART: Treatment-naïve Patients
Monday, 1-4 pm
Room: Hall B |
| 774 |
Efficacy and Safety of Abacavir/Lamivudine Compared to Tenofovir/Emtricitabine in Combination with Once-daily Lopinavir/Ritonavir through 48 Weeks in the HEAT Study
Kimberly Smith*1, D Fine2, P Patel3, N Bellos4, L Sloan5, P Lackey6, D Sutherland-Phillips3, C Vavro3, Q Liao3, and M Shaefer3
1Rush Univ Med Ctr, Chicago, IL, US; 2Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 3GlaxoSmithKline, Research Triangle Park, NC, US; 4Southwest Infectious Disease Assoc, Dallas, TX, US; 5North Texas Infectious Disease Consultants, Dallas, US; and 6ID Consultants, Charlotte, NC, US |
| 775 |
Study M05-730 Primary Efficacy Results at Week 48: Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets Once Daily vs Twice Daily, Co-administered with Tenofovir DF + Emtricitabine in ARV-naïve HIV-1-infected Subjects
J Gathe1, Barbara da Silva*2, M Loutfy3, D Podzamczer4, R Rubio5, S Gibbs2, T Marsh2, C Naylor2, L Fredrick2, and B Bernstein2
1Therapeutic Concepts, Houston, TX, US; 2Abbott Labs, Abbott Park, IL, US; 3Maple Leaf Med Clin, Toronto, Canada; 4Hosp Univ de Bellvitge, Barcelona, Spain; and 5Hosp 12 de Octubre, Madrid, Spain |
| 776 |
Effect of Baseline Characteristics on Treatment Outcomes in ACTG 5142: A Prospective, Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial Treatment of HIV-1 Infection
Sharon Riddler*1, R Haubrich2, G DiRienzo3, L Peeples3, W Powderly4, K Garren5, D Butcher6, J Rooney7, D Havlir8, J Mellors1, and AIDS Clinical Trials Group 5142 Study Team
1Univ of Pittsburgh, PA, US; 2Univ of California, San Diego, US; 3Harvard Sch of Publ Hlth, Boston, MA, US; 4Univ Coll Dublin, Ireland; 5Abbott Labs, Abbott Park, IL, US; 6Bristol-Myers Squibb, Plainsboro, NJ, US; 7Gilead Sci, Foster City CA, US; and 8Univ of California, San Francisco, US |
| 777 |
Analysis of the Relationship between Antiretroviral Medication Adherence and Class-specific Resistance in a Large Prospective Randomized Clinical Trial
Edward Gardner*1, G Peng2, E Telzak3, S Sharma2, K Huppler Hullsiek2, W Burman1, M Chesney4, G Friedland5, R MacArthur6, S Mannheimer7, and The International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
1Denver Publ Hlth, CO, US; 2Univ of Minnesota, Minneapolis, US; 3Bronx-Lebanon Hosp Ctr, NY, US; 4Natl Ctr for Complementary and Alternative Med, NIH, Bethesda, MD, US; 5Yale Univ Sch of Med, New Haven, CT, US; 6Wayne State Univ, Detroit, MI, US; and 7Columbia Univ Coll of Physicians and Surgeons, New York, NY, US |
| 778 |
A 2-Months-off/4-Months-on HAART Is Clinically Not Inferior to Continuous Therapy but Leads to Unacceptable Resistance Rates in African Adults with >350 CD4/mm3 at First Interruption: Final Results of the Trivacan Trial
Christine Danel*1, R Moh1, M L Chaix2, D Gabillard3, B Kouadio1, T Toni4, C Rouzioux2, R Salamon3, E Bissagnene5, X Anglaret3, and ANRS 1269 study group
1Prgm PACCI, Abidjan, Côte d`Ivoire; 2Ctr Hosp Univ Necker, Paris, France; 3INSERM U593, Bordeaux, France; 4CeDReS, Abidjan, Côte d`Ivoire; and 5Infectious and Tropical Diseases Svc, Abidjan, Côte d`Ivoire |
| 779 |
Efficacy and Safety of Dual-PI Regimens for the Treatment of ART-naïve HIV-1 Subjects: 2IP ANRS 127, a Randomized Pilot Study
Roland Landman*1, C Chazallon2, D Descamps1, C Capitant2, G Peytavin1, C Katlama3, G Pialoux4, M Bentata5, J P Aboulker2, P Yeni1, and ANRS 127 study group
1Hosp Bichat-Claude Bernard, Paris, France; 2INSERM SC10, Villejuif, France; 3Hosp Pitie-Salpetriere, Paris, France; 4Hosp Tenon, Paris, France; and 5Hosp Avicenne, Bobigny, France |
| 780 |
Double Protease Inhibitor, RTI-sparing Therapy Regimen in Naïve HIV-1-infected patients: 24-Week Virologic Response Analysis of the LORAN Trial
Ku Ulbricht*1, M Stoll1, G Behrens1, B Salzberger2, H Jessen3, A Jessen3, B Kuhlmann4, A Trein5, H Heiken1, and R Schmidt1
1Hannover Med Sch, Germany; 2Univ of Regensburg, Germany; 3Private Practice Motzstr, Berlin, Germany; 4Praxis Georgstr, Hannover; and 5Private Practice Schwabstr, Stuttgart, Germany |
| 781 |
Effect of a 48-week Lopinavir/r Monotherapy on HIV1-DNA in Blood Cells in the MONARK Trial
Veronique Avettand-Fenoel*1, P Flandre2, M L Chaix1, J Ghosn3, C Delaugerre1, F Raffi4, P NgoVan5, I Cohen-Codar5, J F Delfraissy3, and C Rouzioux1
1Ctr Hosp Univ Necker, Univ Paris-Descartes, France; 2INSERM U720, Paris, France; 3Ctr Hosp Univ Bicetre, Le Kremlin-Bicetre, France; 4Ctr Hosp Univ Nantes, France; and 5Abbott France |
| 782 |
Reasons for Treatment Success with Initial ART: An Analysis of 22,635 Participants in 64 Randomized, Controlled Trials and 14 Prospective Cohorts
Andrew Carr*1 and J Amin2
1St Vincent`s Hosp, Sydney, Australia and 2Natl Ctr in HIV Epi and Clin Res, Univ of New South Wales, Sydney, Australia |
| 783 |
Outcomes of Abacavir- and Efavirenz-based HAART: Comparison of ACTG 5095 Trial Results with Observational Cohort Studies
Michael Mugavero*1, M May2, H Ribaudo3, J Sterne2, S Napravnik4, M Egger5, M Saag1, R Gulick6, and ACTG and ART-CC
1Univ of Alabama at Birmingham, US; 2Univ of Bristol, UK; 3Harvard Sch of Publ Hlth, Boston, MA, US; 4Univ of North Carolina at Chapel Hill, US; 5Univ of Berne, Switzerland; and 6Weill Med Coll of Cornell Univ, New York, NY, US |
| 784 |
Similar Responses Observed in ARV-naïve Patients Treated through Clinical Trials vs Clinical Practice
Justin Routman*1, J Willig1, A Westfall1, S Abroms2, M Varshney1, S Adusumilli1, J Allison1, K Savage1, M Saag1, M Mugavero1, and UAB 1917 HIV/AIDS Clinic Cohort
1Univ of Alabama at Birmingham, US and 2Univ of Pennsylvania, Philadelphia, US |
| 785 |
Prediction of AIDS-defining Illnesses or Death after the Initiation of HAART
Bryan Lau*1,2, S Gange2, G Chander1, J Keruly1, and R Moore1,2
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US and 2Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US |
| 786 |
Nevirapine Administered Once Daily Is as Efficient as a Twice-daily Dosing. A Collaborative Cohort Study
Alexandra Calmy*1, A Nguyen1, J Lange2, M Battegay3, F de Wolf4, P Reiss2, B Hirschel1, F Wit2, and for the Swiss HIV Cohort Study and the Netherlands ATHENA Observational Cohort
1Univ Hosp Geneva, Switzerland; 2Ctr for Poverty-Related Communicable Diseases, Academic Med Ctr, Amsterdam, The Netherlands; 3Univ Hosp Basel, Switzerland; and 4HIV Monitoring Fndn, Amsterdam, The Netherlands |
| 787 |
Single Antiretroviral Switches for Pregnant Women Compared to Non-pregnant Women and Men Who Initiated HAART in the MTCT-Plus Initiative
Patricia Toro*, M Katyal, D Nash, and R Carter
Columbia Univ, New York, NY, US |
|
